Loading...
Derniers dépôts
-
Ludivine Amable, Luis Antonio Ferreira Martins, Remi Pierre, Marcio Do Cruseiro, Ghita Chabab, et al.. Intrinsic factors and CD1d1 but not CD1d2 expression levels control invariant natural killer T cell subset differentiation. Nature Communications, 2023, 14 (1), pp.7922. ⟨10.1038/s41467-023-43424-7⟩. ⟨hal-04328475⟩
-
Nassim Hammoudi, Dominique Cazals-Hatem, Claire Auzolle, Charlotte Gardair, Marjolaine Ngollo, et al.. Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology, 2019, ⟨10.1016/j.cgh.2019.04.045⟩. ⟨hal-02193633⟩
-
Lieven Pouillon, Anne Lamoureux, Guillaume Pineton de Chambrun, Lucine Vuitton, Benjamin Pariente, et al.. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease—A multicenter, retrospective, observational study. Digestive and Liver Disease, 2019, 51 (2), pp.236-241. ⟨10.1016/j.dld.2018.10.022⟩. ⟨hal-02420202⟩
-
Mathurin Fumery, Laurent Peyrin-Biroulet, Stéphane Nancey, Romain Altwegg, Cyrielle Gilletta, et al.. Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks In Crohn's disease: a multicenter study. Journal of Crohn's and Colitis, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩. ⟨hal-02959922⟩
-
Aurelien Amiot, Jerome Filippi, Vered Abitbol, Guillaume Cadiot, David Laharie, et al.. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Alimentary Pharmacology and Therapeutics, 2020, 51 (11), pp.1039-1046. ⟨10.1111/apt.15717⟩. ⟨hal-02798010⟩
Nombre de documents
22
Nombre de notices
47
Répartition par type de documents
Evolution